PDT and PIT induce significant cell death and survival signalling (e.g. EGFR activation, VEGF secretion [64–66], priming cancer cells for concurrent molecular-targeted therapy (e.g. cetuximab), resulting in synergistic tumour reductions [59, 61, 67]. The gene discussed is VEGFA; the disease is cancer.